Skip to main content
. 2023 Nov 9;29(12):3111–3119. doi: 10.1038/s41591-023-02620-0

Table 2.

RR and 95% CI per cumulative active bone marrow dose category and ERR/100 mGy by type of hematological malignancya—analyses stratified on sex, birth cohort and country

ABM dose range (mGy) All hematological malignancies (n = 790) Lymphoid malignancies (n = 578) Myeloid malignancies and AL (n = 203) Leukemia excluding CLL (n = 271)
# RR 95% CI # RR 95% CI # RR 95% CI # RR 95% CI
[0,5) 125 1.00 91 1.00 34 1.00 38 1.00
[5,10) 171 1.10 0.87 1.39 120 1.07 0.81 1.42 47 1.08 0.69 1.71 43 0.79 0.51 1.24
[10,15) 157 1.53 1.20 1.97 123 1.65 1.24 2.20 32 1.16 0.70 1.92 56 1.35 0.87 2.09
[15,25) 165 1.40 1.09 1.80 121 1.41 1.05 1.90 42 1.31 0.80 2.15 66 1.21 0.78 1.89
[25,50) 114 1.87 1.42 2.45 81 1.81 1.32 2.49 32 1.96 1.17 3.29 44 1.61 1.01 2.58
[50+] 58 2.66 1.92 3.70 42 2.64 1.80 3.89 16 2.75 1.47 5.14 24 2.41 1.40 4.17
P for trend 0.02 0.03 0.02 0.02
# ERR/100 mGy 95% CI # ERR/100 mGy 95% CI # ERR/100 mGy 95% CI # ERR/100 mGy 95% CI
790 1.96 1.10 3.12 578 2.01 1.02 3.42 203 2.02 0.47 4.77 271 1.66 0.43 3.74
# RR at 100 mGyb 95% CI # RR at 100 mGy 95% CI # RR at 100 mGy 95% CI # RR at 100 mGy 95% CI
790 2.96 2.10 4.12 578 3.01 2.02 4.42 203 3.02 1.47 5.77 271 2.66 1.43 4.74

Values are shown in RR, ERR/100 mGy and 95% CI.

#, number of cases.

Statistically significant values are shown in bold.

aNo analysis of histiocytic and dendritic cell malignancies or of unspecified malignancies were conducted because of the small number of cases (six and three, respectively).

bNote that the RR at 100 mGy is simply obtained by adding 1 to the ERR/100 mGy.